Without voluntary withdrawals, ODAC to review two more dangling accelerated approvals
The FDA’s Oncologic Drugs Advisory Committee will meet over two days in late September to discuss three controversial drugs, two of which have already won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
